186 related articles for article (PubMed ID: 23800130)
1. Dapagliflozin for the treatment of type 2 diabetes.
Abdul-Ghani MA; DeFronzo RA
Expert Opin Pharmacother; 2013 Aug; 14(12):1695-703. PubMed ID: 23800130
[TBL] [Abstract][Full Text] [Related]
2. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.
Maranghi M; Carnovale A; Durante C; Tarquini G; Tiseo G; Filetti S
Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):125-37. PubMed ID: 25418019
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy for type 2 diabetes: dapagliflozin plus metformin.
Tan X; Hu J
Expert Opin Pharmacother; 2016; 17(1):117-26. PubMed ID: 26567559
[TBL] [Abstract][Full Text] [Related]
5. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin: a review of its use in type 2 diabetes mellitus.
Plosker GL
Drugs; 2012 Dec; 72(17):2289-312. PubMed ID: 23170914
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin combination therapy in type 2 diabetes mellitus.
Yacoub T
Postgrad Med; 2016 Jan; 128(1):124-36. PubMed ID: 26571022
[TBL] [Abstract][Full Text] [Related]
9. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
Avogaro A; Giaccari A; Fioretto P; Genovese S; Purrello F; Giorgino F; Del Prato S
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):763-772. PubMed ID: 28431476
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin for the treatment of type 2 diabetes.
Anderson SL; Marrs JC
Ann Pharmacother; 2012 Apr; 46(4):590-8. PubMed ID: 22433611
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin: a review on efficacy, clinical effectiveness and safety.
Paisley AN; Yadav R; Younis N; Rao-Balakrishna P; Soran H
Expert Opin Investig Drugs; 2013 Jan; 22(1):131-40. PubMed ID: 23127205
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin for the treatment of type 2 diabetes mellitus - an update.
Nicholson MK; Ghazal Asswad R; Wilding JP
Expert Opin Pharmacother; 2021 Dec; 22(17):2303-2310. PubMed ID: 34281456
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin: glucuretic action and beyond.
Balakumar P; Sundram K; Dhanaraj SA
Pharmacol Res; 2014 Apr; 82():34-9. PubMed ID: 24705156
[TBL] [Abstract][Full Text] [Related]
14. [Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].
Sanz-Serra P; Pedro-Botet J; Flores-Le Roux JA; Benaiges D; Chillarón JJ
Clin Investig Arterioscler; 2015; 27(4):205-11. PubMed ID: 25648671
[TBL] [Abstract][Full Text] [Related]
15. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.
Fioretto P; Avogaro A
Expert Opin Pharmacother; 2017 Apr; 18(5):517-527. PubMed ID: 28277831
[TBL] [Abstract][Full Text] [Related]
17. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
Cuypers J; Mathieu C; Benhalima K
Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
[TBL] [Abstract][Full Text] [Related]
18. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
Davis PN; Ndefo UA; Oliver A
J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
